Communiqués AN2 Therapeutics, Inc.

Actions

ANTX

US0373261058

Marché Fermé - Nasdaq Autres places de cotation 21:59:42 04/06/2024			Varia. 5j.	Varia. 1 janv.
2,06 ^USD	-1,90 %		-2,83 %	-89,95 %

16/05	AN2 THERAPEUTICS, INC. : Evercore ISI est neutre sur le titre	ZM
14/05	AN2 Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights	14/05	BU
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights	28/03	BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	12/03	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	03/03	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	24/02	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX	16/02	PR
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	13/02	AQ
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease	12/02	BU
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference	30/01	BU
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights	09/11	BU
AN2 Therapeutics to Present at Upcoming Investor Conferences	06/11	BU
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease	18/10/23	BU
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023	11/10/23	BU
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria	26/09/23	BU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex Lung Disease	14/09/23	AQ
AN2 Therapeutics : Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ~230 patients - Form 8-K	13/09/23	PU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease	13/09/23	BU
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock	16/08/23	BU
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights	10/08/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués AN2 Therapeutics, Inc.

Actions

ANTX

US0373261058

Communiqués

Filtres